Dr. Richard Graham discusses the distinction between real-time data and real-time oversite and how one option may present better results than the other.
Dr. Richard Graham
Advertisement
Dr. Richard Graham is chairman of the board at Tru Technologies.
Articles by Dr. Richard Graham
Dr. Richard Graham details how real-time data review may reduce timelines but also allow for bad data or outcomes.
Dr. Richard Graham explains how FDA’s new program allows for the usage of real-time data during clinical trials.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
The Industry’s Communication and Engagement with FDA
2
Eli Lilly Enters $202 Million Agreement to Acquire Engage Bio
3
Pharma Roundup: Bristol Myers Squibb Enters Strategic Agreement with Anthropic, Incyte and Genesis Expand Strategic Collaboration
4
Pharmaceutical Executive Daily: Eli Lilly Acquires Engage Bio
5